Revenue Showdown: Johnson & Johnson vs GSK plc

Pharma Giants' Revenue Battle: A Decade in Review

__timestamp	GSK plc	Johnson & Johnson
Wednesday, January 1, 2014	23006000000	74331000000
Thursday, January 1, 2015	23923000000	70074000000
Friday, January 1, 2016	27889000000	71890000000
Sunday, January 1, 2017	30186000000	76450000000
Monday, January 1, 2018	30821000000	81581000000
Tuesday, January 1, 2019	33754000000	82059000000
Wednesday, January 1, 2020	34099000000	82584000000
Friday, January 1, 2021	34114000000	78740000000
Saturday, January 1, 2022	29324000000	79990000000
Sunday, January 1, 2023	30328000000	85159000000

Cracking the code

A Decade of Revenue Rivalry: Johnson & Johnson vs GSK plc

In the ever-evolving landscape of the pharmaceutical industry, two giants, Johnson & Johnson and GSK plc, have been vying for dominance over the past decade. From 2014 to 2023, Johnson & Johnson consistently outperformed GSK plc, with revenues averaging 163% higher. In 2023, Johnson & Johnson reached a peak, generating 85 billion USD, marking a 15% increase from 2014. Meanwhile, GSK plc's revenue saw a modest 32% growth over the same period, peaking at 34 billion USD in 2021. This revenue showdown highlights the strategic maneuvers and market dynamics that have shaped these companies' trajectories. As the industry faces new challenges and opportunities, the competition between these titans remains a focal point for investors and analysts alike.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025